A pilot study on the efficacy, pharmacokinetics and safety of atazanavir in patients with end-stage liver disease

Journal of Antimicrobial Chemotherapy

Volumn 62, Issue 6, 2008, Pages 1356-1364

  Guaraldi, Giovanni ^a   Cocchi, Stefania ^a   Motta, Alice ^a   Ciaffi, Sara ^a   Codeluppi, Mauro ^a   Bonora, Stefano ^b   Di Benedetto, Fabrizio ^a   Masetti, Michele ^a   Floridia, Marco ^c   Baroncelli, Silvia ^c   Pinetti, Diego ^a   D'Avolio, Antonio ^b   Bertolini, Alfio ^a   Esposito, Roberto ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Drug drug interactions; HIV; Liver insufficiency; Therapeutic drug monitoring; Unboosted protease inhibitors

Indexed keywords

ABACAVIR; AMPRENAVIR; AMPRENAVIR PHOSPHATE; ATAZANAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; HISTAMINE H2 RECEPTOR AGONIST; LAMIVUDINE; LANSOPRAZOLE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; OMEPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; BILIRUBIN BLOOD LEVEL; BRAIN HEMORRHAGE; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GASTROINTESTINAL DISEASE; GASTROINTESTINAL INTOLERANCE; GILBERT DISEASE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERNATIONAL NORMALIZED RATIO; LACTIC ACIDOSIS; LIVER FAILURE; LIVER TRANSPLANTATION; MALE; PATIENT COMPLIANCE; PILOT STUDY; SIDE EFFECT;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; AREA UNDER CURVE; FEMALE; HIV INFECTIONS; HUMANS; LIVER DISEASES; MALE; MIDDLE AGED; OLIGOPEPTIDES; PILOT PROJECTS; PYRIDINES; SERUM;

EID: 56649108211     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn383     Document Type: Article

References (39)

1. Palella FJ Jr, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853-60.
2. Bica I, McGovern B, Dhar R et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 32: 492-7.
3. Macias J, Melguizo I, Fernandez-Rivera FJ et al. Mortality due to liver failure and impact on survival of hepatitis virus infections in HIV-infected patients receiving potent antiretroviral therapy. Eur J Clin Microbiol Infect Dis 2002; 21: 775-81.
4. Howden CW, Birnie GG, Brodie MJ. Drug metabolism in liver disease. Pharmacol Ther 1989; 40: 439-74.
5. Rodighiero V. Effects of liver disease on pharmacokinetics. An update. Clin Pharmacokinet 1999; 37: 399-431.
6. Robertson SM, Scarsi KK, Postelnick MJ et al. Elevated plasma concentrations of protease inhibitors and nonnucleoside reverse transcriptase inhibitors in patients coinfected with human immunodeficiency virus and hepatitis B or C: Case series and literature review. Pharmacotherapy 2005; 25: 1068-72.
7. Branch RA. Drugs in liver disease. Clin Pharmacol Ther 1998; 64 462-5.
8. Veronese L, Rautaureau J, Sadler BM et al. Single-dose pharmacokinetics of amprenavir, a human immunodeficiency virus type 1 protease inhibitor, in subjects with normal or impaired hepatic function. Antimicrob Agents Chemother 2000; 44: 821-6.
9. Regazzi M, Maserati R, Villani P et al. Clinical pharmacokinetics of nelfinavir and its metabolite M8 in human immunodeficiency virus (HIV)-positive and HIV-hepatitis C virus-coinfected subjects. Antimicrob Agents Chemother 2005; 49: 643-9.
10. Maserati R, Villani P, Seminari E et al. High plasma levels of nelfinavir and efavirenz in two HIV-positive patients with hepatic disease. AIDS (London, England) 1999; 13: 870-1.
11. Spagnuolo V, Gentilini G, De Bona A et al. Liver function parameters in HIV/HCV co-infected patients treated with amprenavir and ritonavir and correlation with plasma levels. New Microbiol 2007; 30: 279-82.
12. Seminari E, De Bona A, Gentilini G et al. Amprenavir and ritonavir plasma concentrations in HIV-infected patients treated with fosamprenavir/ritonavir with various degrees of liver impairment. J Antimicrob Chemother 2007; 60: 831-6.
13. Peng JZ, Pulido F, Causemaker SJ et al. Pharmacokinetics of lopinavir/ritonavir in HIV/hepatitis C virus-coinfected subjects with hepatic impairment. J Clin Pharmacol 2006; 46: 265-74.
14. Alberti A, Clumeck N, Collins S et al. Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol 2005; 42: 615-24.
15. Carosi G, Puoti M, Antonucci G et al. Antiretroviral therapy in chronic liver disease: Focus on HIV/HCV coinfection - statements of the First Italian Consensus Workshop. AIDS Rev 2005; 7: 161-7.
16. Sulkowski MS. Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors. Clin Infect Dis 2004; 38 Suppl 2: S90-7.
17. Qurishi N, Kreuzberg C, Luchters G et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 2003; 362: 1708-13.
18. Malavaud B, Dinh B, Bonnet E et al. Increased incidence of indinavir nephrolithiasis in patients with hepatitis B or C virus infection. Antivir Ther 2000; 5: 3-5.
19. Burger D, Hugen P, Reiss P et al. Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals. AIDS (London, England) 2003; 17: 1157-65.
20. Damle B, Hewlett D Jr, Hsyu PH et al. Pharmacokinetics of nelfinavir in subjects with hepatic impairment. J Clin Pharmacol 2006; 46: 1241-9.
21. Khaliq Y, Gallicano K, Seguin I et al. Single and multiple dose pharmacokinetics of nelfinavir and CYP2C19 activity in human immunodeficiency virus-infected patients with chronic liver disease. Br J Clin Pharmacol 2000; 50: 108-15.
22. Wyles DL, Gerber JG. Antiretroviral drug pharmacokinetics in hepatitis with hepatic dysfunction. Clin Infect Dis 2005; 40: 174-81.
23. The Panel on Clinical Practices for Treatment of HIV infection convened by the Department of Health and Human Services (DHHS) and the Henry J. Kaiser Family Foundation. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. 29 January 2008. http://aidsinfo.nih.gov/Guidelines (22 July 2008, date last accessed).
24. Aube C, Oberti F, Korali N et al. Ultrasonographic diagnosis of hepatic fibrosis or cirrhosis. J Hepatol 1999; 30: 472-8.
25. Colli A, Fraquelli M, Andreoletti M et al. Severe liver fibrosis or cirrhosis: Accuracy of US for detection - analysis of 300 cases. Radiology 2003; 227: 89-94.
26. Di Lelio A, Cestari C, Lomazzi A et al. Cirrhosis: Diagnosis with sonographic study of the liver surface. Radiology 1989; 172: 389-92.
27. Bristol Myers Squibb Company. December 2007. Reyataz (atazanavir sulfate) capsules: Prescribing information. [Online.]. http://www.bms.com (22 July 2008, date last accessed).
28. Wu EY, Wilkinson JM 2nd, Naret DG et al. High-performance liquid chromatographic method for the determination of nelfinavir, novel HIV-1 protease inhibitor, in human plasma. J Chromatogr B Biomed Sci Appl 1997; 695: 373-80.
29. Grossi P, Tumietto F, Costigliola P et al. Liver transplantation in HIV-infected individuals: Results of the Italian national program. Transplantation 2006; 82 Suppl 3 WTC Abstracts 446. Abstract 1139.
30. SPSS software. Chicago, USA: SPSS Inc., 2006. Version 13.0.1.
31. Kaul S, Bassi K, Damle B et al. Pharmacokinetic evaluation of the combination of atazanavir, enteric-coated didanosine, and tenofovir disoproxil fumarate for once-daily antiretroviral regimen. In: Program and Abstracts of the Forty-third Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2003. Abstract A-1616, p. 36. American Society for Microbiology, Washington, DC, USA.
32. Cahn P, Piliero P, Giordano M et al. Atazanavir: Antiretroviral efficacy in HIV-infected patients co-infected with hepatitis B and/or C viruses. In: Program and Abstracts of the Forty-second Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 2002 Abstract H-1730, p. 278. American Society for Microbiology, Washington, DC, USA.
33. Pineda JA, Palacios R, Rivero A et al. Low incidence of severe liver toxicity in patients receiving antiretroviral combinations including atazanavir. J Antimicrob Chemother 2006; 57: 1016-7.
34. Barrios A, Rendon AL, Gallego O et al. Predictors of virological response to atazanavir in protease inhibitor-experienced patients. HIV Clin Trials 2004; 5: 201-5.
35. Busti AJ, Hall RG, Margolis DM. Atazanavir for the treatment of human immunodeficiency virus infection. Pharmacotherapy 2004; 24: 1732-47.
36. Taburet AM, Piketty C, Chazallon C et al. Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2004; 48: 2091-6.
37. Agarwala S, Thal G, Nettles R et al. Further information on the administration of H2-receptor antagonists with atazanavir. J Acquir Immune Defic Syndr 2006; 42: 516.
38. Tomilo DL, Smith PF, Ogundele AB et al. Inhibition of atazanavir oral absorption by lansoprazole gastric acid suppression in healthy volunteers. Pharmacotherapy 2006; 26: 341-6.
39. Khanlou H, Farthing C. Co-administration of atazanavir with proton-pump inhibitors and H2 blockers. J Acquir Immune Defic Syndr 1999) 2005; 39: 503.